SOURCE: BrainStorm Cell Therapeutics, Inc.

BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment Conference

BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate overview of BrainStorm and NurOwn™, its proprietary stem cell platform currently in a phase 2 trial in Amyotrophic Lateral Sclerosis.  Details of the presentation are as follows:


Rodman and Renshaw 16th Annual Global Investment Conference

Date: Tuesday, September 9, 2014

Time: 1:40-2:05 PM EST

Location: New York Palace Hotel, New York, NY

Room: Kennedy II Salon (4th Floor)


The presentation will be webcast, which can be accessed at the following link ( or through the Investor section of the BrainStorm website.


About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company’s website at


Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”,  and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.



BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)

Tony Fiorino, MD, PhD

Chief Executive Officer

Phone: (646) 666-3188


US Investor Contact

LifeSci Advisors, LLC

Michael Rice

Phone: (646) 597-6979



SOURCE: BrainStorm Cell Therapeutics, Inc.